INTETRIX Capsule Ref.[108196] Active ingredients: Tilbroquinol Tilbroquinol and Tiliquinol

Recent studies have confirmed that in healthy volunteers INTETRIX frequently causes an increase in the transaminases levels, which is moderate, asymptomatic and regressive. Consequently, in case of increased transminases levels, and especially in case of icterus, the treatment must be stopped.

Prolonged use of INTETRIX is highly inadvisable due to the risk of peripheral neuropathy (see 4.8. undesirable effects).

INTETRIX must not be prescribed in association with other medicines containing hydroxyquinolines.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose‐galactose malabsorption should not take this medicine.

It is not recommended to use with drugs containing Hydroxyquinoline or its derivatives as an active agent.

There are no reliable data on the potential teratogenic effects of INTETRIX in animals.

Nowadays, there is no pertinent data, nor in sufficient number, to evaluate a potential malformative or foetotoxic effect of this medicine when it is given during pregnancy.

Consequently, the use of medicine is not advised during pregnancy. If having systematic abortion is not recommended, this element leads to a careful attitude and a well positioned antenatal monitoring.

Not applicable.

Increase of transaminases hepatic levels have been reported rarely, the majority of them were asymptomatic and decreased after treatment stopping.

Some rare skin reactions have been reported, either hypersensitive types (urticaria, Quincke’s oedema) or bullous types (fixed pigmented eruption).

Exceptionally, during prolonged treatments, peripheral neuropathies or optical nerve disorders have been reported.

Not applicable.